Diabetes mellitus downregulates expression of connexin43 in rat aortic medial smooth muscle cells and can be reversed by simvastatin and losartan therapy

Chang Gung Medical Journal

Volumn 31, Issue 2, 2008, Pages 136-144

  Sheu, Jiunn Jye ^a   Tsai, Tzu Hsien ^a   Chang, Li Teh ^b   Chiang, Chiang Hua ^c   Youssef, Ali A ^d   Sun, Cheuk Kwan ^a   Chang, Nyuk Kong ^a   Yip, Hon Kan ^a,e  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d Suez Canal University Hospital   (Egypt)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Connexin43; Diabetes mellitus; Pharmacomodulation

Indexed keywords

CONNEXIN 43; GLUCOSE; INSULIN ZINC SUSPENSION; LOSARTAN; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; GAP JUNCTION; GLUCOSE BLOOD LEVEL; IMAGE ANALYSIS; IMMUNOFLUORESCENCE; INSULIN TREATMENT; MALE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RAT; STATISTICAL ANALYSIS; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; BLOTTING, WESTERN; CONNEXIN 43; DIABETES MELLITUS, EXPERIMENTAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOSARTAN; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 42449110703     PISSN: 02558270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
3. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
4. Wissler RW. Update on the pathogenesis of atherosclerosis. Am J Med 1991;91:3S-9S.
5. Wissler RW. Theories and new horizons in the pathogenesis of atherosclerosis and the mechanisms of clinical effects. Arch Pathol Lab Med 1992;116;1281-91.
6. Blackburn JP, Peters NS, Yeh HI, Rothery S, Green CR, Severs NJ. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1219-28.
7. Campbell GR, Campbell JH, Manderson JA, Horrigan S, Rennick RE. Arterial smooth muscle. A multifunctional mesenchymal cell. Arch Pathol Lab Med 1988;112:977-86.
8. Rennick RE, Connat JL, Burnstock G, Rothery S, Severs NJ, Green CR. Expression of connexin43 gap junctions between cultured vascular smooth muscle cells is dependent upon phenotype. Cell Tissue Res 1993;271:323-32.
9. Yeh HI, Lupu F, Dupont E, Severs NJ. Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Arterioscler Thromb Vasc Biol 1997;17:3174-84.
10. Kumar NM, Gilula NB. The gap junction communication channel. Cell 1996;84:381-8.
11. Yamasaki H, Naus CC. Role of connexin genes in growth control. Carcinogenesis 1996;17:1199-213.
12. Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Tsikas D, Boger RH, Forssmann WG, Drexler H, Schieffer B. Angiotensin II receptor-independent anti-inflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770-6.
13. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003;166:129-35.
14. Mach F. Statins as immunomodulatory agents. Circulation 2004;109:II15-7.
15. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81.
16. Laakso MLS. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997;5:294-315.
17. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
18. Barrett-Connor E. Does hyperglycemia really cause coronary heart disease? Diabetes Care 1997;20:1620-3.
19. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-25.
20. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, Ergin A. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-42.
21. Mercado N, Boersma E, Wijns W, Gersh BJ, Morillo CA, de Valk V, van Es GA, Grobbee DE, Serruys PW. Clinical and quantitative coronary angioplasty predictors of coronary restenosis: a comparative analysis from the balloonto-stent era. J Am Coll Cardiol 2001;38:645-52.
22. Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E. Coronary atherosclerosis in Type II diabetes: angiographic findings and clinical outcome. Diabetologia 2000;43:632-41.
23. MacLeod DC, Strauss BH, de Jong M, Escaned J, Umans VA, van Suylen RJ, Verkerk A, de Feyter PJ, Serruys PW. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol 1994;23:59-65.
24. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996;56:3436-40.
25. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-35.
26. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001;88:E14-22.
27. Yeung AC, Tsao P. Statin therapy: beyond cholesterol lowering and anti-inflammatory effects. Circulation 2002;105:2937-8.
28. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003;91:9B-13B.
29. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-31.
30. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881-900.